ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 422

No Added Predictive Value of Serum Calprotectin for Treatment Response to Adalimumab or Etanercept in RA Patients

Lieke Tweehuysen1, Nathan den Broeder1, Leo .A.B. Joosten2, Thomas Vogl3, F.H.J. van den Hoogen4, Rogier Thurlings5 and Alfons A Den Broeder1, 1Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, 2Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands, 3University of Muenster, Muenster, Germany, 4Rheumatology, Rheumatology Centre Sint Maartenskliniek and Radboud university medical center, Ubbergen (Nijmegen), Netherlands, 5Rheumatology, Radboudumc, Nijmegen, Netherlands

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Biologic drugs, biomarkers and rheumatoid arthritis (RA), Clinical Response

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Rheumatoid Arthritis – Clinical Aspects Poster I: Treatment Patterns and Response

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: To date, no clinically useful baseline biomarkers have been found to predict response to TNF inhibitor (TNFi) treatment .1 Calprotectin was shown to be predictive for treatment response to adalimumab (ADA) while no difference in calprotectin levels was found between responders and non-responders  in RA patients treated with etanercept (ETN) and methotrexate.2,3

 

Objectives: To assess the added predictive value of serum calprotectin for  clinical response after 6 months treatment with ADA or ETN in RA patients.

 

Methods: RA patients starting treatment with ADA or ETN in the BIO-TOP study (a prospective cohort study) were included. Patients who discontinued TNFi treatment within 2 months were excluded from analysis. Serum calprotectin was measured at baseline using ELISA. EULAR response was measured at 6 months (good versus moderate/no response). Discontinuation of TNFi before 6 months was regarded as non-response (in case of lack of effect) and clinical response at 3 months was carried forward (when stopped for other reasons). First calprotectin levels were correlated cross-sectionally with several clinical baseline markers. Thereafter, receiver-operator-characteristic (ROC) curves were created for ADA and ETN separately. Finally logistic prediction models were created using backward selection, including baseline characteristics and calprotectin levels to examine the added predictive value of calprotectin.

 

Results: Calprotectin levels and EULAR response were available for 125 patients (ADA (n=50), ETN (n=75)), with 40% of patients achieving EULAR good response. Responders showed significantly higher baseline calprotectin levels: 985 ng/mL (p25-p75: 558-1417) versus 645 ng/mL (p25-p75: 415-973) (p=0.04). Calprotectin levels were significantly correlated to DAS28-CRP (Spearman ρ=0.32, p<0.01) and C-reactive protein (CRP) levels (Spearman ρ=0.57, p<0.01) and significantly higher in rheumatoid factor positive patients (p=0.03). No significant correlation was found between calprotectin and age, gender or ACPA positivity. The area under the curve (AUC) for calprotectin in the ADA and ETN group were 0.68 (95% CI: 0.49-0.88) and 0.49 (95% CI: 0.35-0.63), respectively. The basic model (selected variables: baseline DAS28-CRP and medication used (ADA vs ETN)) showed an AUC of 0.73 (95% CI: 0.64-0.82). The calprotectin added model performed similarly with an AUC of 0.76 (95% CI: 0.67-0.84) (p=0.27).

 

Conclusion: Serum calprotectin is modestly predictive for EULAR good response to ADA but not ETN treatment after 6 months in RA patients. However, calprotectin does not provide additional predictive value over a basic clinical prediction model.

References

1 Cuppen et al. Rheumatology (Oxford) 2016;55(5):826-39

2 Choi IY et al. Ann Rheum Dis 2015;74(3):499-505

3 Obry A et al. PLoS One 2014;9(12):e115800


Disclosure: L. Tweehuysen, None; N. den Broeder, None; L. A. B. Joosten, None; T. Vogl, None; F. H. J. van den Hoogen, Biogen Idec, 5,Celltrion, 5,Janssen Pharmaceutica Product, L.P., 5,Mundipharma, 5,Sandoz, 5; R. Thurlings, None; A. A. Den Broeder, None.

To cite this abstract in AMA style:

Tweehuysen L, den Broeder N, Joosten LAB, Vogl T, van den Hoogen FHJ, Thurlings R, Den Broeder AA. No Added Predictive Value of Serum Calprotectin for Treatment Response to Adalimumab or Etanercept in RA Patients [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/no-added-predictive-value-of-serum-calprotectin-for-treatment-response-to-adalimumab-or-etanercept-in-ra-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/no-added-predictive-value-of-serum-calprotectin-for-treatment-response-to-adalimumab-or-etanercept-in-ra-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology